Cladribine | List of Frontiers open access articles

Original Research

Published on 06 Jun 2022

Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

in Multiple Sclerosis and Neuroimmunology

Tiago Medeiros-Furquim
Sinan Ayoub
Laura J. Johnson
Andrea Aprico
Eze Nwoke
Michele D. Binder
Trevor J. Kilpatrick

Frontiers in Immunology

doi 10.3389/fimmu.2022.678817

13,325 views
4 citations

Original Research

Published on 25 Jul 2023

Molecular signature associated with cladribine treatment in patients with multiple sclerosis

in Multiple Sclerosis and Neuroimmunology

Nicolas Fissolo
Laura Calvo-Barreiro
Herena Eixarch
Ursula Boschert
Luisa M. Villar
Lucienne Costa-Frossard
Mireia Ferrer
Alex Sanchez
Eva Borràs
Eduard Sabidó

Frontiers in Immunology

doi 10.3389/fimmu.2023.1233546

4,423 views
5 citations

Original Research

Published on 16 Feb 2024

Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine

in Multiple Sclerosis and Neuroimmunology

Rikke Holm Hansen
Marina Rode von Essen
Mie Reith Mahler
Stefan Cobanovic
Finn Sellebjerg

Frontiers in Immunology

doi 10.3389/fimmu.2024.1327672

4,319 views
10 citations

Study Protocol

Published on 18 Jul 2024

Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study

in Multiple Sclerosis and Neuroimmunology

Giovanna Borriello
Clara Grazia Chisari
Davide Maimone
Massimiliano Mirabella
Damiano Paolicelli
Francesco Assogna
Sandro Caradonna
Francesco Patti

Frontiers in Neurology

doi 10.3389/fneur.2024.1422078

3,476 views
3 citations

Case Report

Published on 08 Dec 2021

Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report

in Multiple Sclerosis and Neuroimmunology

Riccardo Garbo
Daniela Cutuli
Simone Lorenzut
Gian Luigi Gigli
Daniele Bagatto
Mariarosaria Valente

Frontiers in Neurology

doi 10.3389/fneur.2021.664596

2,954 views
3 citations

Original Research

Published on 07 Mar 2023

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients

in Multiple Sclerosis and Neuroimmunology

Christoph Ruschil
Gisela Gabernet
Constanze Louisa Kemmerer
Mohamed Ali Jarboui
Franziska Klose
Sven Poli
Ulf Ziemann
Sven Nahnsen
Markus Christian Kowarik

Frontiers in Immunology

doi 10.3389/fimmu.2023.1133967

5,439 views
18 citations

Original Research

Published on 27 Feb 2025

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study

in Multiple Sclerosis and Neuroimmunology

Jeske van Pamelen
Carla Rodriguez-Mogeda
Lynn van Olst
Susanne M. A. van der Pol
Maarten L. Boon
Janet de Beukelaar
Oliver H. H. Gerlach
Andries E. Budding
Joep Killestein
Helga E. de Vries

Frontiers in Immunology

doi 10.3389/fimmu.2025.1514762

4,595 views
1 citation

Original Research

Published on 14 Dec 2021

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study

in Multiple Sclerosis and Neuroimmunology

Minodora Dobreanu
Doina Ramona Manu
Ion Bogdan Mănescu
Manuela Rozalia Gabor
Adina Huţanu
Laura Bărcuţean
Rodica Bălaşa

Frontiers in Immunology

doi 10.3389/fimmu.2021.743010

6,063 views
3 citations

Study Protocol

Published on 04 Apr 2024

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy

in Multiple Sclerosis and Neuroimmunology

Massimo Filippi
Laura Ferrè
Chiara Zanetta
Caterina Rizzi
Gabriella Pessina
Francesco Assogna
Maria A. Rocca

Frontiers in Neurology

doi 10.3389/fneur.2024.1379712

4,181 views
1 citation

Brief Research Report

Published on 17 Jun 2020

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

in Multiple Sclerosis and Neuroimmunology

Marcello Moccia
Roberta Lanzillo
Martina Petruzzo
Agostino Nozzolillo
Marcello De Angelis
Antonio Carotenuto
Raffaele Palladino
Vincenzo Brescia Morra

Frontiers in Neurology

doi 10.3389/fneur.2020.00489

4,902 views
18 citations

Original Research

Published on 05 Jan 2026

NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital

in Multiple Sclerosis and Neuroimmunology

Nora Berg Bjørnevoll
Karl Bjørnar Alstadhaug

Frontiers in Neurology

doi 10.3389/fneur.2025.1698334

1,820 views

Case Report

Published on 05 Dec 2022

Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association

in Hematologic Malignancies

Luciana Valvano
Fiorella D’Auria
Vitina Grieco
Teodora Statuto
Filomena Nozza
Giuseppe Pietrantuono
Oreste Villani
Giovanni D’Arena
Daniela Lamorte

Frontiers in Oncology

doi 10.3389/fonc.2022.1069977

2,500 views

Case Report

Published on 22 Sep 2025

Erdheim-Chester disease: unveiling hidden manifestations through two case reports

in Hematologic Malignancies

Guoxia Zhang
Xiaoqing Yang
Lei Fang
Yuxia Cheng
Yanhua Duan
Jing Cui

Frontiers in Oncology

doi 10.3389/fonc.2025.1611907

1,404 views

Review

Published on 29 Nov 2023

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

in Multiple Sclerosis and Neuroimmunology

Hans-Peter Hartung
Bruce A.C. Cree
Michael Barnett
Sven G. Meuth
Amit Bar-Or
Lawrence Steinman

Frontiers in Immunology

doi 10.3389/fimmu.2023.1290666

12,029 views
10 citations

Original Research

Published on 24 Dec 2021

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

in Multiple Sclerosis and Neuroimmunology

Gavin Giovannoni
Patricia K. Coyle
Patrick Vermersch
Bryan Walker
Julie Aldridge
Axel Nolting
Andrew Galazka
Caroline Lemieux
Thomas P. Leist

Frontiers in Immunology

doi 10.3389/fimmu.2021.763433

8,415 views
14 citations

Original Research

Published on 09 Feb 2024

CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis

in Multiple Sclerosis and Neuroimmunology

Damiano Marastoni
Matteo Foschi
Chiara Eccher
Francesco Crescenzo
Valentina Mazziotti
Agnese Tamanti
Albulena Bajrami
Valentina Camera
Stefano Ziccardi
Maddalena Guandalini

Frontiers in Immunology

doi 10.3389/fimmu.2024.1343892

3,950 views
10 citations

Articles

Cladribine Treatment for MS Preserves the Differentiative Capacity of Subsequently Generated Monocytes, Whereas Its Administration In Vitro Acutely Influences Monocyte Differentiation but Not Microglial Activation

Molecular signature associated with cladribine treatment in patients with multiple sclerosis

Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine

Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study

Opportunities and Obstacles Associated With Sequential Immune Reconstitution Therapy for Multiple Sclerosis: A Case Report

Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients

The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study

Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients – An In Vitro Study

Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy

Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials

NEDA-3 using cladribine for multiple sclerosis: effectiveness data from a Norwegian hospital

Case report: Hematologic malignancies concomitant diagnosis of hairy cell leukemia and chronic lymphocytic leukemia: A rare association

Erdheim-Chester disease: unveiling hidden manifestations through two case reports

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets

CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis